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Differentiated thyroid carcinomas (DTCs) that arise from follicular cells account >90% of 
thyroid cancer (TC) [papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 
10%], while medullary thyroid cancer (MTC) accounts <5%. Complete total thyroidec-
tomy is the treatment of choice for PTC, FTC, and MTC. Radioiodine is routinely rec-
ommended in high-risk patients and considered in intermediate risk DTC patients. DTC 
cancer cells, during tumor progression, may lose the iodide uptake ability, becoming 
resistant to radioiodine, with a significant worsening of the prognosis. The lack of specific 
and effective drugs for aggressive and metastatic DTC and MTC leads to additional 
efforts toward the development of new drugs. Several genetic alterations in different 
molecular pathways in TC have been shown in the past few decades, associated with 
TC development and progression. Rearranged during transfection (RET)/PTC gene rear-
rangements, RET mutations, BRAF mutations, RAS mutations, and vascular endothelial 
growth factor receptor 2 angiogenesis pathways are some of the known pathways 
determinant in the development of TC. Tyrosine kinase inhibitors (TKIs) are small organic 
compounds inhibiting tyrosine kinases auto-phosphorylation and activation, most of 
them are multikinase inhibitors. TKIs act on the aforementioned molecular pathways 
involved in growth, angiogenesis, local, and distant spread of TC. TKIs are emerging as 
new therapies of aggressive TC, including DTC, MTC, and anaplastic thyroid cancer, 
being capable of inducing clinical responses and stabilization of disease. Vandetanib and 
cabozantinib have been approved for the treatment of MTC, while sorafenib and lenva-
tinib for DTC refractory to radioiodine. These drugs prolong median progression-free 
survival, but until now no significant increase has been observed on overall survival; 
side effects are common. New efforts are made to find new more effective and safe 
compounds and to personalize the therapy in each TC patient.
Keywords: papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, dedifferentiated thyroid 
cancer, sorafenib, vandetanib, cabozantinib, lenvantinib
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iNTRODUCTiON
The incidence of papillary thyroid cancer (PTC) is increasing (1), 
and it is the predominant endocrine carcinoma (seventh most 
common cause of new cancer in the US women).
The increasing diagnosis of small thyroid cancers (TCs) is 
related to the use of neck ultrasonography and fine needle aspira-
tion (FNA) of thyroid nodules, and also to ionizing radiations 
(2–4% of subjects exposed to radiation during childhood show 
TC) (2), the exposure to fall-out of nuclear explosions or acci-
dents (3), low doses of radiation exposure (4), and the exposure 
to iodine deficient areas, where a higher frequency of follicular 
thyroid cancer (FTC) has been observed (5). Furthermore, auto-
immune thyroiditis has been shown to be a risk factor for PTCs 
(6, 7), and new risk factors are emerging (8, 9).
According to histopathological criteria: (1) differentiated 
thyroid carcinomas (DTCs) that arise from follicular cells 
account >90% of TC and are subdivided into PTC (~90%) or 
FTC (~10%); (2) medullary thyroid cancer (MTC) accounts <5% 
of TC [sporadic (75%); or hereditary forms (25%) that include 
familial MTC, multiple endocrine neoplasia type 2 (MEN) 2A, 
and MEN 2B (10, 11); and (3) anaplastic thyroid cancer (ATC) 
accounts for <2%.
Complete total thyroidectomy is the treatment of choice for 
PTC, FTC, and MTC (12). Radioactive iodine (RAI – 131I) should 
be routinely recommended in high-risk patients and considered 
in intermediate risk DTC patients (13).
Patients with PTC and FTC (after surgery, and eventually 
RAI) are followed by neck ultrasonography and the determina-
tion of basal or thyroid-stimulating hormone (TSH)-stimulated 
thyroglobulin (Tg) (14–16).
More than 90% of patients with DTC have a normal life expec-
tancy (17). The prevalence of TC deaths per year (in relation to 
the number of new cases) is decreased from 15 to 5% in the past 
few decades (10), in contrast with the increasing incidence of the 
disease.
At the diagnosis, ~5% of DTC patients have distant metastasis 
(50% lungs, 25% bones, 20% lungs and bones, and 5% other sites); 
10–15% of patients show recurrences in the follow-up (in the 
thyroid bed, or lymph nodes), with a survival reduction (from 70 
to 50%, at 10 years) (18, 19). Approximately one-third of cancer-
related deaths are associated with neck lesions alone (20).
DTC cancer cells, during tumor progression, may lose the 
iodide uptake ability, becoming resistant to RAI, with a significant 
worsening of the prognosis (17–19).
Poorly differentiated thyroid carcinomas (PDTCs) are a 
subset of thyroid tumors, considered intermediate between DTC 
and ATC, and they are more aggressive than DTC, but less than 
ATC (21, 22).
When tumor progresses, tumor cells lose the iodide uptake 
ability and cancer becomes resistant to the traditional therapeutic 
strategies (23).
In thyrocytes, the sodium/iodine symporter (NIS) (24, 25) 
regulates the iodide trapping, that is a TSH-regulated mechanism, 
at the basolateral surface of the cell with an energy-dependent 
transport, while at the apical surface [where a role has been sug-
gested for the Pendred syndrome (PDS) gene], iodide trapping is 
regulated by a passive transport. At the apical surface, the iodide is 
organified by thyroperoxidase (TPO) and conjugated to tyrosine 
residues on Tg. In primary and metastatic TC, a decrease in NIS 
transcripts has been shown with respect to normal tissues, that 
is more evident in metastases unable to uptake 131I with respect 
to primary cancers, or metastases able to trap it. Also Tg, TPO, 
and PDS gene expressions are decreased in TC with respect to 
normal tissues, overall in metastases with no 131I uptake. These 
data suggest that not only the genetic control over NIS transcrip-
tion occurs but also other mechanisms might be involved in 
this failure to trap 131I (26). A demonstrable 131I uptake by TC 
requires not only a functional and correctly located NIS but also 
the full machinery responsible for iodide retention in the cell. 
Gene therapy studies (where the NIS gene was introduced in 
non-TC cells to promote 131I uptake and induce cytotoxicity) 
confirm this hypothesis.
These studies showed that although an efficient iodine uptake 
was permitted by NIS delivery in the target cells, therapeutic 
effects were observed only with doses of radioiodine beyond the 
ranges used in human beings (26).
In the management of TC patients with high serum Tg levels 
and negative 131I WBS, the effectiveness of fludeoxyglucose-
positron emission tomography (FDG-PET) has been demon-
strated (27).
The ability of TC to trap fludeoxyglucose is consistent with 
studies that have shown a high glucose consumption in TC, 
accompanied by an increase in its transmembrane transport 
due to GLUT-1 overexpression, overall in more aggressive TC 
histotypes, and in the presence of metastases.
In  vivo studies have also shown that the FDG-PET scan 
became more sensitive after administering recombinant human 
TSH, revealing lesions not observed in conditions of TSH sup-
pression, and inducing changes in the surgical management of 
these patients that ameliorate their outcome (27).
In PTC, rearranged during transfection (RET)/PTC rearrange-
ments, RAS and BRAF mutations (28), and β-catenin mutations 
(29) underlie the loss of iodide uptake ability.
Radiotherapy and chemotherapy (doxorubicin) are of limited 
efficacy in the treatment of dedifferentiated TC (30).
Molecular Pathways implicated in Thyroid 
Cancer
Various molecular pathways are implicated in the pathogenesis 
of TC.
Rearranged during transfection is a proto-oncogene encod-
ing a transmembrane protein harboring a tyrosine kinase (TK) 
(31). Rearrangements and mutations able to activate RET have 
been identified in different human cancers (32). In ~40% of 
adult sporadic PTC, RET/PTC rearrangements are present (33); 
RET/PTC1 and RET/PTC3 are the most frequent, and they are 
commonly identified in microcarcinomas and, also, in benign 
thyroid lesions. For these reasons, it has been hypothesized that 
RET/PTC are determinant for tumor initiation, but not progres-
sion (34, 35).
The BRAF kinase belongs to the RAF family proteins (35). After 
activation by RAS binding and protein recruitment to the cell 
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membrane, these kinases phosphorylate and activate MEK, that 
in turn activates ERK and the effectors of the MAPK cascade (33).
Valine to glutamate substitution at residue 600 (V600E) is 
present in ~45% PTC and rarely in FTC and is correlated with 
the tumor aggressiveness at presentation, with the risk of tumor 
recurrence, and with the loss of iodide uptake (33, 36). Other 
activating BRAF mutations have been evidenced in other posi-
tions (for instance, 599 and 601), but their prevalence is definitely 
lower than in 600 (36).
Recently, it has been demostrated that BRAF mutation in PTC 
is associated with a more aggressive behavior, loss of differentia-
tion state, and decreased expression of iodide-metabolizing (37) 
and NIS genes (38).
It has been shown that the BRAF V600E oncogene induces 
TGF-Beta secretion that represses NIS expression and increases 
malignancy in TC (39). Furthermore, targeted BRAF V600E 
expression in thyrocytes of transgenic mice results in TC, which 
undergo dedifferentiation (40).
K-RAS, N-RAS, and H-RAS belong to the RAS gene family, 
encoding intracellular G-proteins that take part in the activation 
of intracellular signaling pathways. RAS mutations are present in 
~10% of PTCs and ~40–50% of FTCs. RAS mutations have been 
strictly linked to a more aggressive TC behavior (41).
PAX8/PPARγ rearrangements (42) are present in ~30–40% 
of conventional FTC and ~5% of oncocytic carcinomas, and 
their presence is often associated with a good prognosis. Tumors 
having PAX8/PPARγ rearrangements commonly do not present 
RAS mutations, and this situation suggests that there are two 
independent pathways linked to PAX8/PPARγ translocations or 
RAS mutations that support the FTC development (42). PAX8/
PPARγ rearrangements are evidenced in 2–10% of follicular 
adenomas, or in the follicular variant of PTC (43). PAX8/PPARγ 
translocations have been shown in 0–1% of PTC.
Increased angiogenesis correlates with a more aggressive 
TC behavior, and the expression of angiogenesis inhibitors or 
stimulators [VEGF/VEGF receptor (VEGFR), epidermal growth 
factor (EGF)/EGFR, platelet-derived growth factor (PDGF)/
PDGFR, fibroblast growth factor (FGF)/FGFR, and hepatocyte 
growth factor (HGF)/c-Met] in TC is associated with clinical 
features of the disease (44). VEGF is more expressed (such as 
its main receptor VEGFR-2) in DTC, and it takes part in neo-
plastic progression and aggressiveness. The dispensing of drugs 
targeting VEGF pathway is actually a therapeutic option for TC 
patients (45).
VEGF A-C, placental growth factor (PlGF) and PDGF A-D 
belong to the VEGF gene family (46). VEGF mediates endothelial 
cell adhesion and migration on extracellular matrix, and this is 
why it is associated with an increased aggressiveness, growth, and 
distant spread of several tumors, including TC (46, 47).
In most DTCs, VEGF is overexpressed and its main receptor 
VEGFR-2 is upregulated (48).
The overexpression of angiopoietin-2 and VEGF in TC pro-
gression and a strong association between tumor size and high 
levels of VEGF and angiopoietin-2 were evidenced. Moreover, an 
increased expression of VEGF-C in lymph node invasive thyroid 
tumors was shown, such as a decrease of the angioinhibitory factor 
thrombospondin-1 in thyroid malignancies capable of hematic 
spread. These data support the idea that angiogenesis factors are 
involved in neoplastic growth, progression, and aggressiveness in 
human TC (49).
For this reason, the systemic administration of antiangiogenic 
drugs targeting components of the VEGF-A-VEGF signal trans-
duction pathway has become a therapeutic option for patients 
with TC (36).
The EGFR cell-surface protein (ErbB-1; HER1 in human 
beings) is a receptor for the EGF-family (50). This protein belongs 
to a subfamily of four related receptor TKs (the ErbB-1, -2, -3, 
and -4). The upregulation or the overactivity of EGFR, caused by 
mutations, has been correlated with different cancers, for exam-
ple, anal and lung cancers (51), and glioblastoma multiforme, and 
in the last one, the most observed mutation is EGFRvIII (52). 
Approximately 30% of all epithelial cancers have mutations, mis-
regulations, or amplifications of EGFR or other family members, 
in fact EGFR participates in the tumor progression and invasion 
in TC, and it is overexpressed in ATC (53).
EGFR is determinant in TC growth and spread, and it is 
strongly expressed in aggressive TC. Its mutations contribute to 
RET activation in TC (54, 55), while RET/PTC1 and RET/PTC3 
upregulate EGFR expression, with a magnitude of induction 
similar to that for TSH (54).
The expression of EGFR1 protein is significantly upregulated 
in PDTC and ATC, and absent or slight in normal thyroid gland 
and in papillary DTC, suggesting that upregulation of EGFR1 
expression may be a molecular marker of dedifferentiation in 
thyroid epithelial carcinomas (56).
High expression of EGFR is associated with lymph node 
metastasis in PTC and plays a role in the progression of TC 
(53, 57, 58).
It has been also reported that a patient with metastatic PDTC 
with an EGFR mutation responded to the treatment with the 
selective EGFR tyrosine kinase inhibitor (TKI) erlotinib (59).
NH2-terminal lysine residues are acetylated on histones, and 
this way is the principal one that controls the cellular differen-
tiation and biological behavior of tumoral cells. The increasing 
rate of the gene transcription is due to a more open chromatin 
configuration, while a closed chromosomal configuration leads 
to transcriptional repression (48). In some cancer cells, the activ-
ity of histone acetyltransferase or histone deacetylase (HDAC) 
has been dysregulated (60). Vorinostat, depsipeptide, valproic 
acid, belinostat, and panobinostat have an antineoplastic effect 
on TC cells (61).
Thyroid Cancer: Targeted Therapy
RET Pathway
One of the most explored chemical template is the pyrazolo[3,4-
d]pyrimidine (PP) heterocyclic core, shown to be a useful scaffold 
for the obtainment of effective TKIs (Table 1). Actually, deriva-
tives belonging to this structural class show a large spectrum 
of activity. Different PP compounds act as: (a) Abl inhibitors 
and antiproliferative agents against human leukemia cell lines; 
(b) Src kinase inhibitors in neuroblastoma, medulloblastoma, 
and osteosarcoma; (c) phospholipase D inhibitors in different 
neoplasias; and (d) urokinase plasminogen activator inhibitors, 
in breast cancer.
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Recently, CLM3, [(R)-1-phenethyl-N-(1-phenylethyl)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine], has been shown to inhibit 
RET-TK, BRAF, VEGFR-2, and EGFR and to exert antiangiogenic 
activity. In human TC cell lines, CLM3 showed antiproliferative 
and proapoptotic effects and also an antiangiogenic effect (82–84).
It has been also shown that CLM3 and CLM29 (another 
pyrazolo[3,4-d]pyrimidine, inhibiting RET, EGFR, and VEGFR, 
with antiangiogenic activity) (82) inhibited the migration of pap-
illary dedifferentiated thyroid cancer (DePTC) cells. Moreover, 
CLM3 (85), CLM29 (82), and CLM94 (86) have been demon-
strated to exert antineoplastic activity in primary ATC cells. 
CLM3 and CLM29 had an inhibitory effect independently from 
the presence of V600EBRAF mutation both in DePTC and in 
ATC. A newly produced DePTC cell line (AL), with V600EBRAF 
mutation, was able to grow in nu/nu mice when inoculated sc. 
CLM3 and CLM29 increased TSP-1 expression in the AL cell 
line. The antineoplastic activity of CLM3 and CLM29 could 
depend on the antiproliferative effect linked to apoptosis in the 
tumoral cells and the inhibition of migration and the neoplastic 
neovascularization. In fact, a significant decrease of microvessels 
was observed, in vivo, in the CLM3-treated tumors.
More recently, CLM29 was tested both in primary MTC 
(pMTC) cells from surgical samples, and in TT cells with 
the C634W RET mutation (87). In pMTC and TT cells, the 
proliferation was inhibited significantly (similarly in pMTC 
cells with/without RET mutation) increasing the apoptosis, 
by CLM29. Upon the injection of TT cells sc in CD nu/nu 
mice, neoplastic masses were observed after 20–30 days from 
TABLe 1 | Principal involved pathways and relative targeted therapies in thyroid cancer.
involved pathways Drugs Thyroid cancer Responses Authors
PR SD PD PFS (months)
Raf Sorafenib 30 DeTC 23.3% 53.3% 7% 21 Gupta-Abramson et al. (62)
Sorafenib 41 DeTC 15% 56% 15 Kloos et al. (63)
Sorafenib 207 DeTC 10.8 Brose et al. (64)
VEGF Vandetanib 30 MTC 20% 53% 3% 27.9 Wells et al. (65)
Vandetanib 231 MTC 45% 42% Wells et al. (66)
Vandetanib 145 DeTC 8% 57% 11.1 Leboulleux et al. (67)
Motesanib 93 DeTC 14% 35% 8% 40 weeks Sherman et al. (68)
Motesanib 93 DeTC 48% MTC 40 weeks DeTC Bass et al. (69)
91 MTC 48 weeks MTC
Axitinib 49 DeTC 30% 38% 7% 18.1 Cohen et al. (70)
11 MTC
Axitinib 52 MTC 35% 35% 16 Locati et al. (71)
Sunitinib 7 MTC 28% PR + 3% CR 46% 17% 12.8 Carr et al. (72)
28 DeTC
Sunitinib 11 DeTC 18% PR + 9% CR 45% 27% 11.5 Dìez et al. (73)
Cabozantinib 37 MTC 29% Kurzrock et al. (74)
Cabozantinib 15 DeTC 53% 40% Cabanillas et al. (75)
Pazopanib 37 DeTC 49% 73% 11.7 Bible et al. (76)
Lenvatinib 58 DeTC 50% 28% 5% 12.6 Cabanillas et al. (77)
Lenvatinib 261 DeTC 63 PR% + 2% 18.3 Schlumberger et al. (78)
Vascular disrupting Combretastatin 18 ATC 33% 7.4 weeks Cooney et al. (79)
EGFR Gefitinib 27 DeTC 12% 3.7 Pennell et al. (80)
Histone deacetylase Vorinostat 16 DTC 0% 0% 36% Woyach et al. (81)
3 MTC
ATC, anaplastic thyroid cancer; DeTC, dedifferentiated thyroid cancer; MTC, medullary thyroid cancer; PR, partial response; PD, progressive disease; PFS, progression-free survival; 
SD, stable disease.
xenotransplantation; CLM29 (50  mg/kg/day) significantly 
decreased tumor growth and microvessel density. These data 
demonstrated that CLM29 has antineoplastic activity in MTC 
in vitro, and in vivo, enabling an eventual future clinical evalu-
ation (87).
Other pyrazolo[3,4-d]pyrimidines (88), such as PP1 (89), PP2 
(90), and Si34 (88), have been studied in TC. PP1 pyrazolopy-
rimidine had an important inhibitory effect on RET kinase (89).
PP2 reduced RET/PTC1-mediated MAPK signaling and 
inhibited the invasive phenotype and the proliferation of human 
thyroid carcinoma cells with RET/PTC1 rearrangements (90). 
PP2 inhibited c-Src and related kinases (91), and for this reason, 
it was not selective for RET.
Thus, other no direct effects of PP2 mediated in vivo by the 
inhibition of other kinases could not be excluded
This situation was similar for Si34 (88), which inhibits the TK 
c-Src in 2 human tumor cell lines deriving from MTC, named TT 
and MZ-CRC-1.
Raf Kinase Pathway
Sorafenib (Nexavar®) is (a bi-aryl urea) multitargeted TKI, with 
inhibitor activity against VEGFR-2 and 3, c-Kit, PDGFR, RET/
PTC, and Raf kinases (more avidly, C-Raf than B-Raf), and the 
Raf/Mek/Erk pathway (MAPK pathway); it has been also shown 
to induce apoptosis through downregulation of Mcl-1 (92, 93).
Sorafenib is approved for the treatment of primary kidney 
cancer (advanced RCC) and advanced primary liver cancer 
(HCC).
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From the data shown by several phase II trials (62, 63), a 
multicenter (DECISION trial), double-blind randomized phase 
III study, that evaluated sorafenib (with respect to placebo), in 
advanced/metastatic RAI-refractory DTC (with lesions without 
iodine uptake in a post RAI scan performed during a low iodine 
diet and with adequate TSH elevation and/or recombinant 
human TSH stimulation) (64) has been conducted. Patients were 
randomized 1:1 to receive placebo or sorafenib. The initial group 
comprises a population of 417 patients (207 treated with sorafenib 
and 210 with placebo), while the final group was constituted by 
416 patients (207 treated with sorafenib and 209 with placebo). 
The inclusion criteria were: age > 18 years, life expectancy not 
fewer than 12 weeks, locally advanced or metastatic DTC (PTC, 
FTC, Hurtle cell, or PDTC) with at least one lesion (measurable 
by magnetic resonance or computer tomography imaging) and 
disease progression within 14 months. Other inclusion criteria 
were a performance status <2 according to Eastern Cooperative 
Oncology Group, adequate TSH suppression (<0.5  mU/L), 
absence of renal and liver failure, and adequate bone marrow 
function. Patients were excluded, if they had yet received any 
treatment with TKI, monoclonal antibodies against VEGFRs or 
other targeted agents, chemotherapy or thalidomide. Efficacy 
and safety of sorafenib have been assessed every 56  days (two 
cycles) and 28 days (1 cycle) for 8 months and after every 56 days, 
respectively. At the end of the study, median progression-free 
survival (PFS) was significantly improved in the patients admin-
istered with sorafenib (10.8 months) than the ones with placebo 
(5.8  months), and it got better in all prespecified clinical and 
genetic biomarker subgroups, independent from the presence/
absence of mutations (64).
A phase III trial, conducted by Bayer, involving 417 patients, 
is still ongoing (94).
VEGF Pathway
Vandetanib (ZD6474; an orally active TKI) has a low molecular 
weight and a good inhibitory activity of VEGFR-2, and targets 
VEGFR-3, EGFR, and RET kinases, too (95).
After several trials (65), the international randomized phase 
III ZETA trial (66) compared ZD6474 (300  mg daily; versus 
placebo) in 331 patients with MTC: vandetanib prolonged PFS 
(hazard ratio [HR], 0.46; 95% CI, 0.31–0.69; P < 0.001).
FDA approved Vandetanib in April 2011, being the first TKI 
able to treat adult patients with agressive MTC (66).
One hundred forty-five patients with locally advanced/metastatic 
DTC, 72 of whom administered with vandetanib (300 mg/daily) and 
73 with placebo, improved PFS as shown in a double-blind phase 
II study (67). TKI-treated patients had a higher PFS (11.1 months) 
than the ones who received placebo (5.9 months). Partial response 
(PR) and stable disease (SD) in patients who received TKI were 8% 
and 57%, while for the ones treated with placebo were 5% and 42%, 
respectively. The tolerability and safety were in agreement with the 
ones previously reported by other papers (67).
Various phase I (96) and phase II trials have been performed 
with (AMG 706) motesanib diphosphate, an ATP-competitive 
inhibitor of VEGFR-1, -2, and -3, PDGFR, and Kit, administered 
orally 125  mg/day in patients with metastatic or advanced TC 
(68, 69).
Motesanib diphosphate was administered to 93 DTC patients 
[of whom 57 were PTC (61%)] (68): PR was obtained in 14% 
of the patients, and SD in 35% for 24 weeks (or longer). In 81% 
of patients, serum Tg diminished with respect to the baseline. 
Seven patients (8%) had tumor progression and median PFS was 
40 weeks. The most frequent adverse events (AEs) were diarrhea 
(59%), hypertension (56%), asthenia (46%), and weight loss (40%), 
and the most frequent grade 3 AE was hypertension (25%) (69). 
Approximately 22% of patients showed primary hypothyroidism.
One hundred eighty-four patients (93 DTC and 91 MTC) 
were administered in a phase II trial with motesanib (125 mg/
day orally) for as far as 48 weeks (97); SD was obtained by 48% 
of MTC patients for not fewer than 24 weeks. Median PFS was 
40 and 48 weeks for DTC and MTC patients, respectively (69).
The second-generation inhibitor of VEGFR-1, -2, and -3, 
PDGFR, and c-Kit, axitinib (AG-013736) (97, 98), inhibited 
PDGFR and Kit in cell-based assays more than 10-fold less 
potently than the other VEGF-TKIs (99).
Sixty patients with advanced TC (30 PTC, 15 FTC, and 11 MTC) 
were treated with axitinib (5 mg twice daily), in a phase II trial 
(70). Thirty-eight percent of patients (3 MTC, 12 PTC, and 7 FTC) 
obtained SD for at least 16 weeks, while 30% (2 MTC, 8 PTC, and 
6 FTC) achieved PR. Median PFS was 72.4 weeks (18.1 months). 
Axitinib had an insignificant effect on KIT, as the authors showed 
a reduction of soluble VEGFR-2, -3, and Kit of 32%, 35%, and 13% 
respectively, whereas serum VEGF was 2.8-fold higher (70).
Another phase II trial (71) was conducted with axitinib (5 mg 
twice daily) in 52 patients with metastatic or locally advanced 
MTC or DTC. The objective response (OR) rate was 35% (18 PR), 
and SD was shown in 18 patients for >16  weeks. Median PFS 
was 16 months, and median overall survival was 27 months. The 
quality of life was maintained during the treatment. This paper 
indicates that axitinib could be considered a supplementary 
option therapy for patients with advanced TC (71).
The multitargeted TKI sunitinib (SU011248) is a selective 
inhibitor of VEGFR-1, -2, and -3, PDGFR, c-KIT, and RET/PTC 
subtypes 1 and 3 (100). It has been approved to treat gastrointes-
tinal stromal tumor (GIST), or clear-cell renal carcinoma (101), 
and it is now investigated in other human cancer types. As AEs, 
palmar-plantar erythrodysesthesia, fatigue, diarrhea, hyperten-
sion, neutropenia, and hypothyroidism have been identified (102).
Sunitinib strongly inhibits the growth of TPC1 cells that have 
a RET/PTC rearrangement (103).
Another preclinical study (104) indicated that the clinical 
applications of sunitinib should be directed by genotyping; the 
study evaluated the different inhibitory mechanisms of this drug 
against BRAF mutations, or RET/PTC rearrangement in cell lines 
or orthotopic TC mouse model, showing that it inhibited RET/
PTC (but not BRAF) mutated cells (104).
Twenty-eight patients with aggressive DTC and 7 patients 
with MTC were administered with sunitinib (37.5 mg) on con-
tinuous basis in the largest open-label phase II trial (72), showing 
a complete response (CR) in 3%, PR in 28%, and SD in 46% of 
patients. The most frequent toxicities were neutropenia (34%), 
leukopenia (31%), hand/foot syndrome (17%), diarrhea (17%), 
and fatigue (11%). A decrease in FDG-PET uptake predicted PR 
or stabilization of the disease (72).
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The importance of the therapy with sunitinib in progressive 
metastatic DTC patients has also been reported by more recently 
published papers (73).
The oral multiple-receptor kinase inhibitor cabozantinib 
(XL184) inhibits VEGFR-1 and -2, C-MET, RET, c-Kit, FLT3, 
and Tie-2 (105, 106).
A phase I trial on cabozantinib was carried out in 37 patients 
with MTC (74): PR was obtained in 10 (29%) of 35 MTC patients 
with measurable disease.
Fifteen DTC patients received cabozantinib with 140 mg free 
base (the same as 175 mg salt form) daily: PR was shown in 8/15 
patients (53%), while SD in 6/15 patients (40%) (75).
On the basis of the obtained data, FDA approved cabozantinib 
for MTC treatment (107).
Also pazopanib (GW786034) is a VEGFR-1, -2, and -3, PDGFR, 
and c-Kit inhibitor, approved for the treatment of renal cell carci-
noma (108). In a phase II trial, 39 patients (37/39 were assessed) 
with advanced DTC were administered with pazopanib. A PR was 
achieved in 18 patients (49%), even if no CR was evidenced, with 
800 mg/day orally; progressive disease (PD) was seen ultimately 
in 27 patients (73%). No differences were revealed between PTC 
and FTC. Tg decreased not <30% in 28/32 patients (88%) (76).
It has been recently demonstrated that the combination of 
pazopanib with paclitaxel (a microtubule inhibitor) led to a 
synergistic antitumor activity in ATC cells and xenografts linked 
to mitotic catastrophe. A pilot clinical translation of pazopanib/
paclitaxel treatment showed a lasting effect in a patient with 
metastatic ATC. The aforementioned data indicated that combin-
ing pazopanib and paclitaxel could be effective in the therapeutic 
approach in ATC (109).
Lenvatinib (E7080) is an oral, multitargeted TKI of VEGFR-1, 
-2, and -3, FGFR-1, -2, -3, and -4, PDGFR α, RET, and KIT (110). 
According to the observed data in a phase II study in patients with 
aggressive TC (77), a phase III study of lenvatinib in Differentiated 
Cancer of the Thyroid (SELECT) (78) has been conducted. In 
this phase III study, patients with progressive TC (refractory to 
iodine-131) were randomly assigned to receive lenvatinib (261 
patients; at a daily dose of 24 mg per day in 28-day cycles), or 
placebo (131 patients). In case of disease progression, patients 
treated with placebo received open-label lenvatinib. Median PFS 
was significantly longer (18.3  months) in the lenvatinib group 
than in the placebo one (3.6 months; P < 0.001). All the aforemen-
tioned subgroups achieved a PFS associated with lenvatinib. In the 
lenvatinib group, there were 4 CR and 165 PR, with a response rate 
of 64.8% versus 1.5% in the placebo group (P < 0.001). Median OS 
was not significantly different in either groups. Patients receiving 
lenvatinib presented AEs: hypertension (in 68% of the patients), 
diarrhea (59%), fatigue or asthenia (59%), decreased appetite 
(50%), decreased weight (46%), and nausea (41%). Because of 
severe AEs, discontinuation of the study drug happened in 37 
patients receiving lenvatinib (14%) and 3 receiving placebo (2%). 
Drug-related deaths occurred in 6 (out of 20 deaths occurring in 
the treatment period) patients treated with lenvatinib (78).
Vascular Disrupting Drug
Combretastatin A4 phosphate (a microtubule depolymerizing 
agent) has an effect on tumor vascular networks, leading both 
severe interruption of tumor blood flow and necrosis to the 
tumoral mass (111).
In a phase I study, one ATC patient treated with combretastatin 
showed a CR and was alive 30 months after the treatment (112).
In a phase II study, 18 patients with metastatic ATC, who had 
not received previously any therapy for advanced disease, were 
treated with combretastatin intravenously at 45 mg/m2 (79). The 
authors did not observe any ORs and 33% of the subjects had 
SD, with a reported PFS of 7.4  weeks. The observed AEs were 
vomiting, mild-to-moderate headache, nausea, and tumor pain.
EGFR Pathway
The EGFR inhibitor gefitinib (ZD1839) was employed for the first 
time in non-small-cell lung cancer (113) and can inhibit with 
efficacy the ATC proliferation inducing apoptosis in vitro (114).
Pennell et  al. (80) conducted a phase II trial in 27 patients. 
Eighteen of 27 patients had an advanced and RAI-refractory DTC 
and were administered with gefitinib (250  mg/day orally). The 
more reported AEs and toxicities were rash in 52% of patients, 
diarrhea (41%), anorexia (11%), nausea (9%). PR was not obtained 
from any patient; SD was in 48% of patients at 3 months, and in 
24% and 12% at 6 and 12 months, respectively. Five among 15 
patients (33%) with detectable serum Tg had a strong decrease of 
it (<90%) for >6 months (80).
As the cytotoxic activity of doxorubicin is increased by the 
inactivation of EGFR, that also decreases its extrusion; gefitinib 
and doxorubicin together have been proposed to treat metastatic 
FTC and ATC (115).
It has been recently shown that there was a PFS of >11 months 
in a man with metastatic PDTC, showing an EGFR mutation, 
who responded to the therapy with the selective EGFR TKI 
erlotinib (59).
Histone Deacetylase Inhibitors
US FDA has approved (116) the oral HDAC inhibitor vorinostat 
(suberoylanilide hydroxamic acid), able to block TC cell growth 
inducing apoptosis in vitro (117), for the treatment of cutaneous 
T-cell lymphoma. Vorinostat (beginning with the dose of 200 mg 
b.i.d.) has been evaluated in 19 TC patients (16 DTC and 3 MTC), 
and none of them had a response (81).
Moreover, owing to the absence of response and a sudden 
death (grade 5) and a pulmonary embolus (grade 4), a phase II 
trial about romidepsin in DTC patients was interrupted in 20 
patients (118).
PPARγ
PPARγ belongs to a superfamily of nuclear hormone receptors 
(119). Activation of PPARγ isoforms causes both antineoplastic 
(119) and anti-inflammatory effects (120) in different kinds of 
mammalian cells. In 2001, a study showed that ligands for PPARγ 
were able to induce apoptosis and to block the proliferation in 
human PTC cells (121), to stop distant metastasis of BHP18–21 
tumors in nude mice in vivo (121), and to induce the process of 
redifferentiation in TC (122).
For these reasons, Hayashi et al. examined the expression of 
both PPARγ gene and protein in five human ATC cell lines (123). 
An elevated level of the PPARγ gene and protein expression was 
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found in five ATC cell lines than in PTC in vitro. Cell proliferation 
was inhibited by PPARγ ligands inducing the process of apoptosis. 
Moreover, PPARγ ligands downregulated the invasive potential of 
five ATC cell lines (123).
The in vitro biologic effects of the two PPARγ agonists ciglita-
zone and rosiglitazone (RGZ) in ATC cell lines were studied by 
Aiello et al. (124) showing that RGZ increased the expression of 
thyroid-specific differentiation markers.
In an in  vitro study conducted by Marlow et  al. (125), it 
has been shown that the high-affinity PPARγ agonist, RS5444, 
inducing the cyclin-dependent kinase inhibitor p21, is able to 
inhibit the proliferation of ATC cells and that the reactivation 
of suppressed RhoB is a critical step for the growth inhibition 
of ATC.
Recently, Antonelli et  al. have demonstrated in  vitro that 
RGZ and pioglitazone (both PPARγ agonists) can inhibit the 
cell growth, and the proliferation in primary cultured cells from 
human ATC, established from different patients (126).
Moreover, the same group conducted another in vitro study in 
which the results of chemosensitivity tests with PPARγ agonists in 
primary ATC cells obtained directly from FNA are quite similar 
than those obtained from surgical biopsies (127, 128).
The aim of a recent phase I study (129), conducted on 15 ATC 
patients, was to determine the potential effectiveness of paclitaxel 
and efatutazone (an oral PPARγ agonist) at different doses (seven 
of them received 0.15 mg, six received 0.3 mg, and two received 
0.5 mg of efatutazone). Only one subject, treated with 0.3 mg of 
efatutazone, had a PR from day 69 to day 175; seven patients had 
SD. Forty-eight and 68 days were the median times to progression 
in patients treated with 0.15 and 0.3 mg of efatutazone, and the 
median survival was 98 versus 138 days, respectively. Grade 3 or 
greater AEs related to the treatment were exhibited in 10 subjects, 
in particular, 2 of these were anemia and edema. The combination 
between efatutazone and paclitaxel resulted in safety and toler-
ability and had biologic activity (129).
CONCLUSiON
In spite of the generally good prognosis of TC, ~5% of patients 
will develop metastatic disease, not responsive to traditional 
therapies. The knowledge of alterations in different molecular 
pathways in TC (RET/PTC rearrangements, RET mutations, 
BRAF mutations, RAS mutations, and VEGFR-2 expression) has 
permitted the development of new targeted drugs. TKIs are small 
organic compounds inhibiting TKs auto-phosphorylation and 
activation and acting on the aforementioned molecular pathways 
involved in growth, angiogenesis, local, and distant spread of TC. 
TKIs are emerging as new therapies of aggressive TC, including 
differentiated TC, MTC, and ATC. Vandetanib and cabozantinib 
have been approved for the treatment of MTC; sorafenib and 
lenvatinib have been approved for DTC refractory to RAI. These 
drugs prolong median PFS, but until now, no significant increase 
has been observed on overall survival; side effects are common. 
New efforts are made to find new, more effective, and safe com-
pounds and to personalize the therapy in each TC patient.
AUTHOR CONTRiBUTiONS
SMF, PF, UP, GM, EB, SU, PM, and AA gave substantial contribu-
tion in the conception and design of the work and in writing the 
paper. AA revised it critically for important intellectual content. 
SMF, PF, UP, GM, EB, SU, PM, and AA gave the final approval 
of the version to be published. SMF, PF, UP, GM, EB, SU, PM, 
and AA agreed to be accountable for all aspects of the work in 
ensuring that questions related to the accuracy or integrity of any 
part of the work are appropriately investigated and resolved.
ReFeReNCeS
1. Colonna M, Uhry Z, Guizard A, Delafosse P, Schvartz C, Belot A, et al. Recent 
trends in incidence, geographical distribution, and survival of papillary 
thyroid cancer in France. Cancer Epidemiol (2015) 39:511–8. doi:10.1016/j.
canep.2015.04.015 
2. Schlumberger M, Chevillard S, Ory K, Dupuy C, Le Guen B, de Vathaire F. 
[Thyroid cancer following exposure to ionizing radiation]. Cancer Radiother 
(2011) 15:394–9. doi:10.1016/j.canrad.2011.05.002 
3. Antonelli A, Miccoli P, Derzhitski VE, Panasiuk G, Solovieva N, Baschieri 
L. Epidemiologic and clinical evaluation of thyroid cancer in children from 
the Gomel region (Belarus). World J Surg (1996) 20:867–71. doi:10.1007/
s002689900132 
4. Suzuki K, Yamashita S. Low-dose radiation exposure and carcinogenesis. Jpn 
J Clin Oncol (2012) 42:563–8. doi:10.1093/jjco/hys078 
5. Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet 
Diabetes Endocrinol (2015) 3:286–95. doi:10.1016/S2213-8587(14)70225-6 
6. Antonelli A, Ferri C, Fallahi P, Cazzato M, Ferrari SM, Sebastiani M, et al. 
Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. 
Eur J Endocrinol (2007) 156:431–7. doi:10.1530/EJE-06-0591 
7. Antonelli A, Delle Sedie A, Fallahi P, Ferrari SM, Maccheroni M, Ferrannini 
E, et al. High prevalence of thyroid autoimmunity and hypothyroidism in 
patients with psoriatic arthritis. J Rheumatol (2006) 33:2026–8. 
8. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Barani L, et  al. 
Thyroid cancer in HCV-related chronic hepatitis patients: a case-control 
study. Thyroid (2007) 17:447–51. doi:10.1089/thy.2006.0194 
9. Antonelli A, Ferri C, Fallahi P, Nesti C, Zignego AL, Maccheroni M. Thyroid 
cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol 
(2002) 20:693–6. 
10. Ward EM, Thun MJ, Hannan LM, Jemal A. Interpreting cancer trends. Ann N 
Y Acad Sci (2006) 1076:29–53. doi:10.1196/annals.1371.048 
11. Pusztaszeri MP, Bongiovanni M, Faquin WC. Update on the cytologic and 
molecular features of medullary thyroid carcinoma. Adv Anat Pathol (2014) 
21:26–35. doi:10.1097/PAP.0000000000000004 
12. Miccoli P, Antonelli A, Spinelli C, Ferdeghini M, Fallahi P, Baschieri L. 
Completion total thyroidectomy in children with thyroid cancer secondary 
to the Chernobyl accident. Arch Surg (1998) 133:89–93. doi:10.1001/
archsurg.133.1.89 
13. Lamartina L, Cooper DS. Radioiodine remnant ablation in low-risk differ-
entiated thyroid cancer: the “con” point of view. Endocrine (2015) 50:67–71. 
doi:10.1007/s12020-014-0523-4 
14. Antonelli A, Miccoli P, Ferdeghini M, Di Coscio G, Alberti B, Iacconi P, et al. 
Role of neck ultra-sonography in the follow-up of patients operated on for 
thyroid cancer. Thyroid (1995) 5:25–8. doi:10.1089/thy.1995.5.25 
15. Antonelli A, Miccoli P, Fallahi P, Grosso M, Nesti C, Spinelli C, et al. Role of neck 
ultra-sonography in the follow-up of children operated on for thyroid pap-
illary cancer. Thyroid (2003) 13:479–84. doi:10.1089/105072503322021142 
16. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid 
Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, 
Haugen BR, Kloos RT, Lee SL, et al. Revised American thyroid association 
management guidelines for patients with thyroid nodules and differentiated 
thyroid cancer. Thyroid (2009) 19:1167–214. doi:10.1089/thy.2009.0110 
November 2015 | Volume 6 | Article 1768
Ferrari et al. Aggressive Thyroid Cancer New Therapies
Frontiers in Endocrinology | www.frontiersin.org
17. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, 
et al. Papillary thyroid cancer: time course of recurrences during postsur-
gery surveillance. J Clin Endocrinol Metab (2013) 98:636–42. doi:10.1210/
jc.2012-3401 
18. Gruber JJ, Colevas AD. Differentiated thyroid cancer: focus on emerging 
treatments for radioactive iodine-refractory patients. Oncologist (2015) 
20:113–26. doi:10.1634/theoncologist.2014-0313 
19. D’Agostino M, Sponziello M, Puppin C, Celano M, Maggisano V, Baldan 
F, et  al. Different expression of TSH receptor and NIS genes in thyroid 
cancer: role of epigenetics. J Mol Endocrinol (2014) 52:121–31. doi:10.1530/
JME-13-0160 
20. Baudin E, Schlumberger M. New therapeutic approaches for meta-
static thyroid carcinoma. Lancet Oncol (2007) 8:148–56. doi:10.1016/
S1470-2045(07)70034-7 
21. Burman KD. Is poorly differentiated thyroid cancer poorly characterized? J 
Clin Endocrinol Metab (2014) 99:1167–9. doi:10.1210/jc.2014-1549 
22. Patel KN, Shaha AR. Poorly differentiated thyroid cancer. Curr Opin Otolaryngol 
Head Neck Surg (2014) 22:121–6. doi:10.1097/MOO.0000000000000037 
23. Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, et  al. 
Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed 
Pharmacother (2008) 62:559–63. doi:10.1016/j.biopha.2008.07.056 
24. Haugen BR. Management of the patient with progressive radioiodine 
non-responsive disease. Semin Surg Oncol (1999) 16:34–41. doi:10.1002/
(SICI)1098-2388(199901/02)16:1<34::AID-SSU7>3.0.CO;2-2 
25. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/
iodide symporter: a key transport system in thyroid cancer cell metabolism. 
Eur J Endocrinol (1999) 141:443–57. doi:10.1530/eje.0.1410443 
26. Braga-Basaria M, Ringel MD. Clinical review 158: beyond radioiodine: a 
review of potential new therapeutic approaches for thyroid cancer. J Clin 
Endocrinol Metab (2003) 88:1947–60. doi:10.1210/jc.2002-021863 
27. Mazzaferri EL, Massoll N. Management of papillary and follicular (differenti-
ated) thyroid cancer: new paradigms using recombinant human thyrotropin. 
Endocr Relat Cancer (2002) 9:227–47. doi:10.1677/erc.0.0090227 
28. Antonelli A, Ferri C, Ferrari SM, Sebastiani M, Colaci M, Ruffilli I, et al. New 
targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol 
(2010) 2010:921682. doi:10.1155/2010/921682 
29. Soares P, Lima J, Preto A, Castro P, Vinagre J, Celestino R, et  al. Genetic 
alterations in poorly differentiated and undifferentiated thyroid carcinomas. 
Curr Genomics (2011) 12:609–17. doi:10.2174/138920211798120853 
30. Sun XS, Sun SR, Guevara N, Marcy PY, Peyrottes I, Lassalle S, et al. Indications 
of external beam radiation therapy in non-anaplastic thyroid cancer and 
impact of innovative radiation techniques. Crit Rev Oncol Hematol (2013) 
86:52–68. doi:10.1016/j.critrevonc.2012.09.007 
31. Fallahi P, Mazzi V, Vita R, Ferrari SM, Materazzi G, Galleri D, et  al. New 
therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 
16:6153–82. doi:10.3390/ijms16036153 
32. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic 
and therapeutic target in sporadic and hereditary endocrine tumors. Endocr 
Rev (2006) 5:535–60. doi:10.1210/er.2006-0017 
33. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic tar-
gets. Mod Pathol (2008) 21(Suppl 2):S37–43. doi:10.1038/modpathol.2008.10 
34. Marotta V, Guerra A, Sapio MR, Vitale M. RET/PTC rearrangement in 
benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol 
(2011) 165:499–507. doi:10.1530/EJE-11-0499 
35. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer (2005) 
12:245–62. doi:10.1677/erc.1.0978 
36. Fallahi P, Giannini R, Miccoli P, Antonelli A, Basolo F. Molecular diagnostics 
of fine needle aspiration for the presurgical screening of thyroid nodules. 
Curr Genomics (2014) 15:171–7. doi:10.2174/1389202915999140404100347 
37. Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort 
of patients with sporadic papillary thyroid carcinomas: correlation withmore 
aggressive phenotype and decreased expression of iodide-metabolizing 
genes. Cancer (2009) 115:972–80. doi:10.1002/cncr.24118 
38. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, et  al. 
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with 
a lower expression of both thyroperoxidase and sodium iodide symporter 
genes in papillary thyroid cancer. Endocr Relat Cancer (2008) 15:511–20. 
doi:10.1677/ERC-07-0130 
39. Riesco-Eizaguirre G, Rodrìguez I, De la Vieja A, Costamagna E, Carrasco 
N, Nistai M, et al. The BRAFV600E oncogene induces transforming growth 
factor beta secretion leading to sodium iodide symporter repression and 
increased malignancy in thyroid cancer. Cancer Res (2009) 69:8317–25. 
doi:10.1158/0008-5472.CAN-09-1248 
40. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, et al. Targeted 
expression of BRAFV600E in thyroid cells of transgenic mice results in 
papillary thyroid cancers that undergo dedifferentiation. Cancer Res (2005) 
65:4238–45. doi:10.1158/0008-5472.CAN-05-0047 
41. Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist 
(2013) 18:926–32. doi:10.1634/theoncologist.2013-0072 
42. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW II, 
Tallini G, et al. RAS point mutations and PAX8-PPAR gamma rearrangement 
in thyroid tumors: evidence for distinct molecular pathways in thyroid fol-
licular carcinoma. J Clin Endocrinol Metab (2003) 88:2318–26. doi:10.1210/
jc.2002-021907 
43. Castro P, Rebocho AP, Soares RJ, Magalhães J, Roque L, Trovisco V, et  al. 
PAX8-PPARgamma rearrangement is frequently detected in the follicular 
variant of papillary thyroid carcinoma. J Clin Endocrinol Metab (2006) 
91:213–20. doi:10.1210/jc.2005-1336 
44. Tan A, Xia N, Gao F, Mo Z, Cao Y. Angiogenesis-inhibitors for meta-
static thyroid cancer. Cochrane Database Syst Rev (2010):CD007958. 
doi:10.1002/14651858.CD007958.pub2 
45. Cao Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine 
organs. Nat Rev Endocrinol (2014) 10:530–9. doi:10.1038/nrendo.2014.114 
46. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, et al. Vascular 
endothelial growth factor gene and protein: strong expression in thyroid-
itis and thyroid carcinoma. J Endocrinol (1999) 161:41–9. doi:10.1677/
joe.0.1610041 
47. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogen-
esis. Circ Res (2007) 100:782–94. doi:10.1161/01.RES.0000259593.07661.1e 
48. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of 
epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 6:38–51. 
doi:10.1038/nrc1779 
49. Bunone G, Vigneri P, Mariani L, Butó S, Collini P, Pilotti S, et al. Expression 
of angiogenesis stimulators and inhibitors in human thyroid tumors and cor-
relation with clinical pathological features. Am J Pathol (1999) 155:1967–76. 
doi:10.1016/S0002-9440(10)65515-0 
50. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat 
Oncol Biol Phys (2004) 59:21–6. doi:10.1016/j.ijrobp.2003.11.041 
51. Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V, 
Hénin D, et al. Growth factor receptor expression in anal squamous lesions: 
modifications associated with oncogenic human papillomavirus and human 
immunodeficiency virus. Hum Pathol (2009) 40:1517–27. doi:10.1016/j.
humpath.2009.05.010 
52. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular 
target in cancer therapy. Endocr Relat Cancer (2001) 8:83–96. doi:10.1677/
erc.0.0080083 
53. Knauf JA. Does the epidermal growth factor receptor play a role in the 
progression of thyroid cancer? Thyroid (2011) 21:1171–4. doi:10.1089/
thy.2011.2111.ed 
54. Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, et al. 
RET/PTC-induced cell growth is mediated in part by epidermal growth 
factor receptor (EGFR) activation: evidence for molecular and functional 
interactions between RET and EGFR. Cancer Res (2008) 68:4183–91. 
doi:10.1158/0008-5472.CAN-08-0413 
55. Masago K, Asato R, Fujita S, Hirano S, Tamuré Y, Kanda T, et al. Epidermal 
growth factor receptor gene mutations in papillary thyroid carcinoma. Int J 
Cancer (2009) 124:2744–9. doi:10.1002/ijc.24250 
56. Landriscina M, Pannone G, Piscazzi A, Toti P, Fabiano A, Tortorella S, et al. 
Epidermal growth factor receptor 1 expression is upregulated in undifferenti-
ated thyroid carcinomas in humans. Thyroid (2011) 21:1227–34. doi:10.1089/
thy.2011.0172 
57. Tang C, Yang L, Wang N, Li L, Xu M, Chen GG, et al. High expression of 
GPER1, EGFR and CXCR1 is associated with lymph node metastasis in 
papillary thyroid carcinoma. Int J Clin Exp Pathol (2014) 7:3213–23. 
58. Sethi K, Sarkar S, Das S, Rajput S, Mazumder A, Roy B, et al. Expressions of 
CK-19, NF-κB, E-cadherin, β-catenin and EGFR as diagnostic and prognostic 
November 2015 | Volume 6 | Article 1769
Ferrari et al. Aggressive Thyroid Cancer New Therapies
Frontiers in Endocrinology | www.frontiersin.org
markers by immunohistochemical analysis in thyroid carcinoma. J Exp Ther 
Oncol (2011) 9:187–99. 
59. Lote H, Bhosle J, Thway K, Newbold K, O’Brien M. Epidermal growth factor 
mutation as a diagnostic and therapeutic target in metastatic poorly differen-
tiated thyroid carcinoma: a case report and review of the literature. Case Rep 
Oncol (2014) 7:393–400. doi:10.1159/000364856 
60. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone 
deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 
1:194–202. doi:10.1038/35106079 
61. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as 
anti-neoplastic agents. Cancer Lett (2009) 280:192–200. doi:10.1016/j.
canlet.2009.03.013 
62. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger 
M, Ransone K, et  al. Phase II trial of sorafenib in advanced 
thyroid cancer. J Clin Oncol (2008) 26:4714–9. doi:10.1200/
JCO.2008.16.3279 
63. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II 
trial of sorafenib in metastatic thyroid cancer. J Clin Oncol (2009) 27:1675–84. 
doi:10.1200/JCO.2008.18.2717 
64. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib 
in radioactive iodine-refractory, locally advanced or metastatic differentiated 
thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (2014) 
384:319–28. doi:10.1016/S0140-6736(14)60421-9 
65. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib 
for the treatment of patients with locally advanced or metastatic hereditary 
medullary thyroid cancer. J Clin Oncol (2010) 28:767–72. doi:10.1200/
JCO.2009.23.6604 
66. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. 
Vandetanib in patients with locally advanced or metastatic medullary thy-
roid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2012) 
30:134–41. doi:10.1200/JCO.2011.35.5040 
67. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada 
A, et al. Vandetanib in locally advanced or metastatic differentiated thyroid 
cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol (2012) 
13:897–905. doi:10.1016/S1470-2045(12)70335-2 
68. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, et al. 
Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J 
Med (2008) 359:31–42. doi:10.1056/NEJMoa075853 
69. Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, 
et al. Biomarkers as predictors of response to treatment with motesanib in 
patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 
(2010) 95:5018–27. doi:10.1210/jc.2010-0947 
70. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. 
Axitinib is an active treatment for all histologic subtypes of advanced thy-
roid cancer: results from a phase II study. J Clin Oncol (2008) 26:4708–13. 
doi:10.1200/JCO.2007.15.9566 
71. Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, et al. Treatment 
of advanced thyroid cancer with axitinib: phase 2 study with pharmacoki-
netic/pharmacodynamic and quality-of-life assessments. Cancer (2014) 
120:2694–703. doi:10.1002/cncr.28766 
72. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et  al. 
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory 
differentiated thyroid cancer and metastatic medullary carcinoma of the thy-
roid with functional imaging correlation. Clin Cancer Res (2010) 16:5260–8. 
doi:10.1158/1078-0432.CCR-10-0994 
73. Dìez JJ, Iglesias P, Alonso T, Grande E. Activity and safety of sunitinib in 
patients with advanced radioactive iodine-refractory differentiated thyroid 
carcinoma in clinical practice. Endocrine (2015) 48:582–8. doi:10.1007/
s12020-014-0356-1 
74. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, 
et  al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, 
in patients with medullary thyroid cancer. J Clin Oncol (2011) 29:2660–6. 
doi:10.1200/JCO.2010.32.4145 
75. Cabanillas ME, Brose MS, Ramies DA, Lee Y, Miles D, Sherman SI. 
Antitumor Activity of Cabozantinib (XL184) in a Cohort of Patients (PTS) 
with Differentiated Thyroid Cancer (DTC). (Abstract #5547) ASCO Annual 
Meeting. Chicago, IL (2012).
76. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, 
et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic 
differentiated thyroid cancers: results of a phase 2 consortium study. Lancet 
Oncol (2010) 11:962–72. doi:10.1016/S1470-2045(10)70203-5 
77. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson 
B, et  al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, 
radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and 
biomarker assessment. Cancer (2015) 121:2749–56. doi:10.1002/cncr.29395 
78. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. 
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J 
Med (2015) 372:621–30. doi:10.1056/NEJMoa1406470 
79. Cooney MM, Savvides P, Agarwala S, Wang D, Flick S, Bergant S, et al. Phase 
II study of combretastatin A4 phosphate (CA4P) in patients with advanced 
anaplastic thyroid carcinoma (ATC). J Clin Oncol (2006) 24:A5580. 
80. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, et al. A 
phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 
(2008) 18:317–23. doi:10.1089/thy.2007.0120 
81. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, 
et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat 
in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin 
Endocrinol Metab (2009) 94:164–70. doi:10.1210/jc.2008-1631 
82. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Fioravanti A, et al. 
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with 
antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid 
cancer. J Clin Endocrinol Metab (2011) 96:E288–96. doi:10.1210/jc.2010-1905 
83. Bocci G, Fioravanti A, La Motta C, Orlandi P, Canu B, Di Desidero T, et al. 
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyro-
sine kinase inhibitor, alone and in combination with SN-38 on endothelial 
and cancer cells. Biochem Pharmacol (2011) 81:1309–16. doi:10.1016/j.
bcp.2011.03.022 
84. Sartini S, Coviello V, Bruno A, La Pietra V, Marinelli L, Simorini F, et  al. 
Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, 
synthesis, functional evaluation, and molecular modeling studies. J Med 
Chem (2014) 57:1225–35. doi:10.1021/jm401358b 
85. Antonelli A, Bocci G, Fallahi P, La Motta C, Ferrari SM, Mancusi C, et al. 
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic proper-
ties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J 
Clin Endocrinol Metab (2014) 99:E572–81. doi:10.1210/jc.2013-2321 
86. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Ruffilli I, et al. CLM94, 
a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is 
active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin 
Endocrinol Metab (2012) 97:E528–36. doi:10.1210/jc.2011-1987 
87. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Corrado A, et al. 
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic 
activity in medullary thyroid cancer in vitro and in vivo. Mol Cell Endocrinol 
(2014) 393:56–64. doi:10.1016/j.mce.2014.06.002 
88. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, et al. Growth 
inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine 
derivates. J Endocrinol Invest (2007) 30:RC31–4. doi:10.1007/BF03349220 
89. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, 
et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET onco-
genes. Cancer Res (2002) 62:1077–82. 
90. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo 
RM, et  al. Efficient inhibition of RET/papillary thyroid carcinoma onco-
genic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]
pyrimidine (PP2). J Clin Endocrinol Metab (2003) 88:1897–902. doi:10.1210/
jc.2002-021278 
91. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, 
et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase 
inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 
(1996) 271:695–701. doi:10.1074/jbc.271.2.695 
92. Fallahi P, Ferrari SM, Santini F, Corrado A, Materazzi G, Ulisse S, et  al. 
Sorafenib and thyroid cancer. BioDrugs (2013) 27:615–28. doi:10.1007/
s40259-013-0049-y 
93. Ruan M, Liu M, Dong Q, Chen L. Iodide- and glucose-handling gene expres-
sion regulated by sorafenib or cabozantinib in papillary thyroid cancer. J Clin 
Endocrinol Metab (2015) 100:1771–9. doi:10.1210/jc.2014-3023 
94. Bayer. Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-
Refractory Differentiated Thyroid Cancer [ClinicalTrials.Gov Identifier: 
NCT00984282] (2015). Available from: https://clinicaltrials.gov/ct2/show/
NCT00984282?term=NCT00984282&rank=1
November 2015 | Volume 6 | Article 17610
Ferrari et al. Aggressive Thyroid Cancer New Therapies
Frontiers in Endocrinology | www.frontiersin.org
95. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, 
et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, 
efficiently blocks oncogenic RET kinases. Cancer Res (2002) 62:7284–90. 
96. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, et al. Safety, 
pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, 
in patients with advanced solid tumors. J Clin Oncol (2007) 25:2369–76. 
doi:10.1200/JCO.2006.07.8170 
97. Kelly RJ, Rixie O. Axitinib – a selective inhibitor of the vascular endothelial 
growth factor (VEGF) receptor. Target Oncol (2009) 4:297–305. doi:10.1007/
s11523-009-0126-9 
98. Bagcchi S. Axitinib: VEGF inhibition in advanced thyroid cancer. Lancet 
Oncol (2014) 15:e310. doi:10.1016/S1470-2045(14)70249-9 
99. Hu-Lowe D, Hallin M, Feeley R, Zou H, Rewolinski D, Wickman G, et al. 
Characterization of potency and activity of the VEGF/PDGF receptor tyro-
sine kinase inhibitor AG013736. Proc Am Assoc Cancer Res (2002) 43:A5357. 
100. Rini BI. Sunitinib. Expert Opin Pharmacother (2007) 8:2359–69. 
doi:10.1517/14656566.8.14.2359 
101. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic 
renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther (2007) 
29:1338–53. doi:10.1016/j.clinthera.2007.07.022 
102. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol (2010) 
80:592–601. doi:10.1016/j.bcp.2010.05.003 
103. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, et  al. An orally 
administered multitarget tyrosine kinase inhibitor, SU11248, is a novel 
potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. 
J Clin Endocrinol Metab (2006) 91:4070–6. doi:10.1210/jc.2005-2845 
104. Jeong WJ, Mo JH, Park MW, Choi IJ, An SY, Jeon EH, et al. Sunitinib inhibits 
papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF 
mutation. Cancer Biol Ther (2011) 12:458–65. doi:10.4161/cbt.12.5.16303 
105. Durante C, Russo D, Verrienti A, Filetti S. XL184 (cabozantinib) for medul-
lary thyroid carcinoma. Expert Opin Investig Drugs (2011) 20:407–13. doi:10
.1517/13543784.2011.559163 
106. Cui JJ. Inhibitors targeting hepatocyte growth factor receptor and their 
potential therapeutic applications. Expert Opin Ther Pat (2007) 17:1035–45. 
doi:10.1517/13543776.17.9.1035 
107. Goldenberg MM. Pharmaceutical approval update. P T (2013) 38:86–95. 
108. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et  al. 
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of 
a randomized phase III trial. J Clin Oncol (2010) 28:1061–8. doi:10.1200/
JCO.2009.23.9764 
109. Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, 
et  al. Pazopanib enhances paclitaxel-induced mitotic catastrophe in 
anaplastic thyroid cancer. Sci Transl Med (2013) 5:166ra3. doi:10.1126/
scitranslmed.3004358 
110. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi 
T, et  al. E7080, a novel inhibitor that targets multiple kinases, has potent 
antitumor activities against stem cell factor producing human small cell 
lung cancer H146, based on angiogenesis inhibition. Int J Cancer (2008) 
122:664–71. doi:10.1002/ijc.23131 
111. Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting 
agents: novel therapeutic agents for oncology and other pathologies. Int J 
Exp Pathol (2009) 90:284–94. doi:10.1111/j.1365-2613.2009.00651.x 
112. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, 
et al. A phase I pharmacokinetic and translational study of the novel vascular 
targeting agent combretastatin a-4 phosphate on a single-dose intravenous 
schedule in patients with advanced cancer. Cancer Res (2002) 62:3408–16. 
113. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa 
N, et  al. Prospective phase II study of gefitinib for chemotherapy-naive 
patients with advanced non-small-cell lung cancer with epidermal growth 
factor receptor gene mutations. J Clin Oncol (2006) 24:3340–6. doi:10.1200/
JCO.2005.05.4692 
114. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, et al. 
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thy-
roid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic 
thyroid cancer. Clin Cancer Res (2004) 10:8594–602. doi:10.1158/1078-0432.
CCR-04-0690 
115. Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, 
et al. Gefitinib inhibition of drug resistance to doxorubicin by inactivating 
ABCG2 in thyroid cancer cell lines. Arch Otolaryngol Head Neck Surg (2007) 
133:1022–7. doi:10.1001/archotol.133.10.1022 
116. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval sum-
mary: vorinostat for treatment of advanced primary cutaneous T-cell lym-
phoma. Oncologist (2007) 12:1247–52. doi:10.1634/theoncologist.12-10-1247 
117. Luong QT, O’Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor 
activity of suberoylanilide hydroxamic acid against thyroid cancer cell line 
in vitro and in vivo. Clin Cancer Res (2006) 12:5570–7. doi:10.1158/1078-
0432.CCR-06-0367 
118. Sherman EJ, Su YB, Lyall A, Schöder H, Fury MG, Ghossein RA, et  al. 
Evaluation of romidepsin for clinical activity and radioactive iodine reuptake 
in radioactive iodine-refractory thyroid carcinoma. Thyroid (2013) 23:593–9. 
doi:10.1089/thy.2012.0393 
119. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxi-
some proliferator-activated receptor gamma agonists. Lancet Oncol (2004) 
5:419–29. doi:10.1016/S1470-2045(04)01509-8 
120. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, 
et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in 
Graves’ ophthalmopathy: modulation by peroxisome proliferator- activated 
receptor-gamma agonists. J Clin Endocrinol Metab (2006) 91:614–20. 
doi:10.1210/jc.2005-1689 
121. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for per-
oxisome proliferator-activated receptor gamma inhibit growth and induce 
apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol 
Metab (2001) 86:2170–7. doi:10.1210/jcem.86.5.7493 
122. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen 
BR. Retinoid X receptor-gamma and peroxisome proliferator-activated 
receptor-gamma expression predicts thyroid carcinoma cell response to 
retinoid and thiazolidinedione treatment. Mol Cancer Ther (2004) 3:1011–20. 
123. Hayashi N, Nakamori S, Hiraoka N, Tsujie M, Xundi X, Takano T, et  al. 
Antitumor effects of peroxisome proliferator activate receptor gamma 
ligands on anaplastic thyroid carcinoma. Int J Oncol (2004) 24:89–95. 
124. Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, et  al. 
Peroxisomal proliferator-activated receptor-gamma agonists induce partial 
reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer 
cells. Endocrinology (2006) 147:4463–75. doi:10.1210/en.2005-1610 
125. Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, 
et  al. Reactivation of suppressed RhoB is a critical step for the inhibition 
of anaplastic thyroid cancer growth. Cancer Res (2009) 69:1536–44. 
doi:10.1158/0008-5472.CAN-08-3718 
126. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Minuto 
M, et  al. Thiazolidinediones and antiblastics in primary human 
anaplastic thyroid cancer cells. Clin Endocrinol (2009) 70:946–53. 
doi:10.1111/j.1365-2265.2008.03415.x 
127. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Marchetti I, et al. 
Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of 
primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. 
Eur J Endocrinol (2008) 159:283–91. doi:10.1530/EJE-08-0190 
128. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Barani L, et  al. 
Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle 
aspiration used for chemosensitivity tests. Clin Endocrinol (2008) 69:148–52. 
doi:10.1111/j.1365-2265.2008.03182.x 
129. Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee 
ME, et al. Efatutazone, an oral PPAR-γ agonist, in combination with pacli-
taxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin 
Endocrinol Metab (2013) 98:2392–400. doi:10.1210/jc.2013-1106 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Ferrari, Fallahi, Politti, Materazzi, Baldini, Ulisse, Miccoli and 
Antonelli. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
